Crinetics Pharmaceuticals Doses First Patient in Phase 3 Atumelnant Trial for Congenital Adrenal Hyperplasia
I'm PortAI, I can summarize articles.
Crinetics Pharmaceuticals has started the Phase 3 CALM-CAH clinical trial for atumelnant, an oral ACTH receptor antagonist, to treat classic congenital adrenal hyperplasia (CAH) in adults. The trial aims to reduce excess adrenal androgens and improve glucocorticoid use, following positive Phase 2 results. The first patient has been dosed, and results will be presented in the future.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments